GLP1R and Alzheimer disease: If the improvements in memory and synaptic plasticity, reduction in neurotoxic amyloid oligomer levels, numbers of amyloid plaques and of the inflammation response, and increased neurogenesis observed in previous studies [11,23] translate to humans, GLP-1 analogues such as Liraglutide or GLP-1 receptor agonists such as exendin-4 and lixisenatide are promising new treatment strategies for Alzheimer's disease.